drugset / Trial / NCT01736358

The Use of Intranasal Ketoralac for Pain Management (Sprix)

NCT01736358

Phase 4 Terminated 50 enrolled Montefiore Medical Center
RandomizedParallel-groupDouble-blindSupportive care

Summary

Despite an overall reduction in the perioperative complication rate, post operative pain management after ureteroscopic removal of stones (URS) remains a major factor delaying discharge of patients. The investigators hypothesize that perioperative usage of intranasal ketorolac will provide a reduction in post operative opioid requirements, better post operative pain control, higher anesthesia satisfaction and faster recovery.

Timeline

Start
2012-10
Primary completion
2014-06
Completion
2014-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 31.5 mg Intranasal

Indications